Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/95224
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Inflammatory myopathy with anti-SRP antibodies: case series of a South Australian cohort
Author: Basnayake, S.
Blumbergs, P.
Tan, J.
Roberts-Thompson, P.
Limaye, V.
Citation: Clinical Rheumatology, 2015; 34(3):603-608
Publisher: Springer
Issue Date: 2015
ISSN: 0770-3198
1434-9949
Statement of
Responsibility: 
Sajini K Basnayake, Peter Blumbergs, Ju Ann Tan, Peter J Roberts-Thompson, Vidya Limaye
Abstract: Myopathy associated with anti-signal recognition particle (SRP) antibodies is a rare form of myopathy, which is thought to be distinct from classic polymyositis.We sought to determine the demographic, clinical and histopathological features of patients with anti-SRP antibodies. Hence we undertook an audit of patients with histologically-confirmed myositis who had anti-SRP antibodies. Of 144 patients with inflammatory myositis tested for myositis-specific and myositis-associated antibodies between 2007 and 2011 inclusive, five with anti-SRP antibodies were identified. All five were male, four had severe proximal weakness, one was asymptomatic and three had dysphagia. None had cardiovascular involvement. All patients showed isolated anti-SRP positivity and absence of antinuclear antibodies. Muscle histopathology showed variable myofibre necrosis, and most had an inflammatory infiltrate. Majority showed a favorable response to combination immunosuppressive therapy. Myopathy associated with anti-SRP antibodies is clinically heterogeneous in presentation. Muscle histopathology shows a mixture of necrotic and inflammatory features.
Keywords: Histopathology; muscle biopsy; myositis; necrotizing myopathy; polymyositis . SRP antibodies
Rights: © Clinical Rheumatology 2014
RMID: 0030029798
DOI: 10.1007/s10067-014-2512-7
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.